[144] Amphastar Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice by Floyd Peterson for Amphastar Pharmaceuticals, Inc. (AMPH). The filer notifies a proposed sale of 500 shares of common stock through UBS Financial Services on NASDAQ with an approximate sale date of 09/02/2025 and an aggregate market value listed at $15,450.00. The shares were acquired as RSUs on 06/07/2022. The filing also discloses three sales by the same person in the past three months totaling 1,500 shares on 06/02/2025, 07/02/2025 and 08/01/2025 with combined gross proceeds of $34,984.75. The form includes the required representation that the seller is not aware of undisclosed material adverse information.

Positive

• Disclosure compliance: Proposed sale and recent transactions are reported on Form 144 using a registered broker (UBS).
• Traceable acquisition: Shares were acquired as RSUs on 06/07/2022, and acquisition details are provided.

Negative

• Insider selling activity: The filer sold 1,500 shares in the past three months and proposes to sell another 500 shares, which may be viewed negatively by some investors.
• Missing context: The filing does not state the filer’s relationship to the issuer or provide a 10b5-1 plan adoption date.

Insights

Securities Analyst

TL;DR: Modest insider sales disclosed; proposed sale is small relative to total outstanding shares.

The filing shows a planned sale of 500 shares and prior sales totaling 1,500 shares. With 46,495,077 shares outstanding the transactions are immaterial to company capitalization. Disclosure via Form 144 and use of a registered broker (UBS) indicate compliance with Rule 144 procedures. No purchase plan date or relationship to the issuer is provided in the filing text, and there is no financial performance data in this notice to assess motivation.

Compliance/Risk Analyst

TL;DR: Filing meets procedural requirements but lacks certain contextual details about relationship to issuer.

The document supplies acquisition details (RSU grant date 06/07/2022), broker information, and past sale records, supporting traceability for transfer compliance. The signer affirms absence of undisclosed material adverse information, which is standard. The filing does not state the filer’s relationship to the issuer or any 10b5-1 plan adoption date, limiting assessment of planned trading safeguards.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Avenue 4th Floor New York NY 10010	500	15450.00	46495077	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/07/2022	RSU	Issuer			500	06/07/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Floyd Peterson c/o 11570 SIXTH STREET Rancho Cucamonga CA 91730	Common	08/01/2025	500	10415.75
Floyd Peterson c/o 11570 SIXTH STREET, Rancho Cucamonga CA 91730	Common	06/02/2025	500	12835.05
Floyd Peterson c/o 11570 SIXTH STREET, Rancho Cucamonga CA 91730	Common	07/02/2025	500	11733.95

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for AMPH disclose?

The Form 144 discloses a proposed sale of 500 common shares via UBS on NASDAQ around 09/02/2025, acquired as RSUs on 06/07/2022.

How many shares has the filer sold in the past three months for AMPH?

The filer sold three tranches totaling 1,500 shares on 06/02/2025, 07/02/2025, and 08/01/2025 with combined gross proceeds of $34,984.75.

What is the aggregate market value of the proposed AMPH sale?

The aggregate market value listed for the proposed sale of 500 shares is $15,450.00.

Who is handling the sale and where will the shares trade?

The broker listed is UBS Financial Services, Inc. and the securities are to be sold on NASDAQ.

How many shares outstanding does Amphastar report in the filing?

The filing lists 46,495,077 shares outstanding.